Published in Diabetes Res on January 01, 1994
Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus. Nephrol Dial Transplant (2015) 1.49
Prepubertal onset of diabetes prevents expression of renal cortical connective tissue growth factor. Pediatr Nephrol (2007) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int (1999) 2.87
Criteria used by research and development engineers in the selection of an information source. J Appl Psychol (1968) 2.38
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia (2010) 2.35
Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia (2011) 2.28
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest (2001) 2.20
Taste genes associated with dental caries. J Dent Res (2010) 2.17
Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes (1999) 2.16
Diabetes and hypertension. Australian Diabetes Society position statement. Med J Aust (1995) 2.14
Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia (2011) 1.90
Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation (1998) 1.87
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol (1997) 1.77
Effect of eccentric exercise on position sense at the human forearm in different postures. J Appl Physiol (1985) (2005) 1.75
Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis (2005) 1.71
Reduced bone mass in daughters of women with osteoporosis. N Engl J Med (1989) 1.70
PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int (2001) 1.69
Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int (2006) 1.68
Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes (1991) 1.58
Enamel formation genes are associated with high caries experience in Turkish children. Caries Res (2008) 1.57
Tuftelin, mutans streptococci, and dental caries susceptibility. J Dent Res (2005) 1.57
Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia (1989) 1.57
Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension (2000) 1.56
Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia (2003) 1.55
Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia (2011) 1.51
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia (1995) 1.46
Limitations of cognitive status exams: a case-based discussion. Psychiatry (1996) 1.43
Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia (2006) 1.42
Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes (1994) 1.40
Letter: Death of a pioneer. Vet Rec (1974) 1.39
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes. Med J Aust (2001) 1.39
Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. Kidney Int (1998) 1.36
Maternal and fetal variation in genes of cholesterol metabolism is associated with preterm delivery. J Perinatol (2007) 1.36
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst (2000) 1.35
Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies. Intern Med J (2002) 1.35
Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension (2000) 1.35
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol (2001) 1.35
Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes (2007) 1.29
Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest (1998) 1.29
Muscle spindle signals combine with the sense of effort to indicate limb position. J Physiol (2005) 1.28
MSX1 and TGFB3 contribute to clefting in South America. J Dent Res (2003) 1.28
Targeted scan of fifteen regions for nonsyndromic cleft lip and palate in Filipino families. Am J Med Genet A (2004) 1.24
Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia (1997) 1.24
Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut (2005) 1.23
The emerging role of ACE2 in physiology and disease. J Pathol (2007) 1.22
Template-nucleated alanine-lysine helices are stabilized by position-dependent interactions between the lysine side chain and the helix barrel. Proc Natl Acad Sci U S A (1996) 1.22
Application of American College of Surgeons' field triage guidelines by pre-hospital personnel. J Am Coll Surg (1995) 1.21
A comparison of guanacline with methyldopa in the treatment of hypertension. Med J Aust (1968) 1.21
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia (2001) 1.21
A pH-sensitive fluor, CypHer 5, used to monitor agonist-induced G protein-coupled receptor internalization in live cells. Biotechniques (2002) 1.20
Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol (1999) 1.19
Contributions of PTCH gene variants to isolated cleft lip and palate. Cleft Palate Craniofac J (2006) 1.16
Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int (1997) 1.16
Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med (2004) 1.15
Methyldopa and haemolytic anaemia. Med J Aust (1967) 1.13
Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest (1997) 1.12
Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract (2008) 1.12
Position sense at the human forearm in the horizontal plane during loading and vibration of elbow muscles. J Physiol (2006) 1.09
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets (2005) 1.09
Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes (2000) 1.09
A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int (1998) 1.08
The accuracy of cystatin C and commonly used creatinine-based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabet Med (2007) 1.08
Anaemia in diabetes: Is there a rationale to TREAT? Diabetologia (2006) 1.08
Comparison of the effects of potassium and membrane potential on the calcium-dependent sodium efflux in squid axons. J Physiol (1986) 1.07
Intracellular Ca indicator Quin-2 inhibits Ca2+ inflow via Na/Ca exchange in squid axon. Nature (1985) 1.07
Effect of thyroid status on ouabain binding to the human lymphocyte. J Clin Endocrinol Metab (1982) 1.06
Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver. Biochem J (1986) 1.06
The insulin- and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity. Biochem J (1987) 1.05
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia (2007) 1.05
Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int (2000) 1.03
Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia (2000) 1.03
Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes (2000) 1.03
Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes (1994) 1.02
Damage to human muscle from eccentric exercise after training with concentric exercise. J Physiol (1998) 1.02
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl (1999) 1.00
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia (2001) 1.00
Diabetic nephropathy: from mechanisms to rational therapies. Minerva Med (2006) 1.00
Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes (1994) 1.00
Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab (2000) 0.99
Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia (2007) 0.99
Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds. Bioorg Med Chem Lett (2006) 0.98